Tumor Growth Inhibition And Pharmacokinetic Profile Of NKTR-102 (PEG-Irinotecan) In Multiple Solid Tumors To Be Presented At Upcoming Conference

Nektar Therapeutics (Nasdaq: NKTR) announced that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers. [click link for full article]

More: continued here

Filed under: Cancer on October 11th, 2007